FMI
TVTX icon

F/M Investments’s Travere Therapeutics TVTX Stock Holding History

F/M Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.9M Sell
164,990
-3,426
-2% -$102K 0.33% 66
2025
Q4 		$6.44M Sell
168,416
-27,658
-14% -$899K 0.24% 102
2025
Q3 		$4.69M Buy
196,074
+8,340
+4% +$157K 0.18% 138
2025
Q2 		$2.78M Buy
187,734
+40,269
+27% +$667K 0.1% 199
2025
Q1 		$2.64M Buy
147,465
+36,307
+33% +$737K 0.11% 191
2024
Q4 		$1.94M Buy
+111,158
New +$1.97M 0.07% 233

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

F/M Investments's TVTX Position: Q1 2026 in Review

F/M Investments reduced its Travere Therapeutics (TVTX) stake by 2% in Q1 2026, selling an estimated $102K and leaving 164,990 shares worth $4.9M. The position accounts for 0.33% of the portfolio, ranked #66.

F/M Investments first reported a position in TVTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.44M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • F/M Investments held 164,990 shares of Travere Therapeutics worth $4.9M as of Q1 2026.
  • F/M Investments sold 3,426 Travere Therapeutics shares in Q1 2026, an estimated $102K.
  • Travere Therapeutics made up 0.33% of F/M Investments's portfolio in Q1 2026, its #66 holding.
  • F/M Investments first reported a position in Travere Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • F/M Investments's Travere Therapeutics position peaked at $6.44M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.